Evicenter
P&T meetings

Emiltatug ledadotin (Emi-Le)

Adenoid cystic carcinoma with solid histology or high-grade transformation

Also known as XMT-1660
Manufacturer
Servier
Regulatory submission
Not announced
Launch
Not announced
Last updated
125 sources

Product information and disease descriptionProduct descriptionProduct informationDrug/Drug, drug/disease interactions

Effects of other drugs on Emiltatug ledadotin

1 evidence topic · 1 source

Protocol restriction: prior systemic anticancer therapy washout

“Major surgery within 28 days of starting study treatment, systemic anticancer therapy within the time period of 28 days or 5 half-lives of the prior therapy before starting study treatment (14 days or 5 half-lives for small molecule targeted therapy), whichever is less, or palliative radiation therapy to the chest within 3 months of starting study treatment or to other anatomic sites within 14 days of starting study treatment.” (opens the source at this quote in a new tab)

Clinical drug interaction studies

No evidence found.